Monday, February 16, 2026 2/16/2026

MRI Imaging and Biomarkers for Early Detection of Aggressive Prostate Cancer

Award Number: U01CA239141
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/16/2019
PERIOD OF PERFORMANCE END DATE: 08/31/2025

Group Awards By:

View Award Description

MRI Imaging and Biomarkers for Early Detection of Aggressive Prostate Cancer - Abstract Oversampling and overdiagnosis of prostate cancer are significant management and cost issues that burden our health care system and the individual at risk with unnecessary biopsies and potential complications. The proposed studies will validate recent advances in quantitative prostate multiparametric MRI (mpMRI) techniques, blood biomarkers of aggressive prostate cancer and radiogenomics that relate to increased aggressive cancer risk by our group and collaborators. The overarching goal is to increase the negative predictive value (NPV) for significant prostate cancer and consequently reduce unnecessary biopsies. Central to the proposal are key collaborations between investigators from the Consortium for Imaging and Biomarkers (CIB), Early Detection Research Network (EDRN), and Jet Propulsion Laboratories (JPL). Novel automated techniques for quantitative analysis of mpMRI that identify prostate habitats at risk of harboring significant prostate cancer (Gleason score 3+4 and above or Grade Group (GG)2+) will be combined with improvements in mpMRI-ultrasound fusion biopsies. Our automated pixel-by-pixel 3D prostate habitat risk scoring (HRS) system is superior to the standard prostate lesion classification system, PIRADSv2, and is hypothesized to improve the Negative Predictive Value (NPV) for significant GG2+ cancers (Aim 1). Radiomics will be applied in Aim 1 to refine HRS in the University of Miami MDSelect protocol of 250 men (discovery=150; validation=100). Just as PIRADSv2 is suboptimal because it does not incorporate quantitative imaging information in risk stratification, models of risk based only on histopathologic grading ignore the underlying genomic determinants of outcome. We have shown that radiomics features are associated with underlying gene expression markers of adverse outcome. We propose in Aim 2 to apply newer criteria that incorporate Decipher® score with clinical-pathologic factors to improve the identification of aggressive prostate cancer. Radiomic features associated with these published criteria, termed the Spratt criteria, will improve the NPV for nonaggressive prostate cancer in the MDSelect cohort. We will also collaborate with investigators involved in the EDRN ID-430 clinical trial to test our models in a cohort (n=200) in a less rigorously controlled multi-institutional group with more variability in imaging techniques, vendors and machines. There is also opportunity to further improve risk classification through the analysis of blood-based markers (Aim 3) such as 4Kscore, circulating tumor cells (CTCs) and circulating cancer associated macrophage like (CAML) cells that are early biomarkers of aggressive cancer. The proposed work will test the incremental benefit of adding these serum-based biomarkers to improve the NPV models for significant prostate cancer.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = -$53,755 )
2026	2023	UNIVERSITY OF MIAMI	1320 S DIXIE HWY STE 1200	CORAL GABLES	FL	33146	MIAMI-DADE	USA	Cancer Detection and Diagnosis Research	000	5	1/21/2026	NON-COMPETING CONTINUATION	-$53,755
														Subtotal = -$53,755

Issue Date FY: 2023 ( Subtotal = $557,666 )
2023	2023	UNIVERSITY OF MIAMI	1400 NW 10TH AVE	MIAMI	FL	33136	MIAMI-DADE	USA	Cancer Detection and Diagnosis Research	001	5	9/8/2023	NON-COMPETING CONTINUATION	$557,666
2023	2023	UNIVERSITY OF MIAMI	1400 NW 10TH AVE	MIAMI	FL	33136	MIAMI-DADE	USA	Cancer Detection and Diagnosis Research	002	5	9/19/2023	NON-COMPETING CONTINUATION	$0
2023	2022	UNIVERSITY OF MIAMI	1600 NW 10 AVE	MIAMI	FL	33136	MIAMI-DADE	USA	Cancer Detection and Diagnosis Research	000	4	12/2/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $557,666

Issue Date FY: 2022 ( Subtotal = $570,153 )
2022	2022	UNIVERSITY OF MIAMI	1600 NW 10 AVE	MIAMI	FL	33136	MIAMI-DADE	USA	Cancer Detection and Diagnosis Research	000	4	9/1/2022	NON-COMPETING CONTINUATION	$570,153
														Subtotal = $570,153

Issue Date FY: 2021 ( Subtotal = $592,644 )
2021	2021	UNIVERSITY OF MIAMI	1600 NW 10 AVE	MIAMI	FL	33136	MIAMI-DADE	USA	Cancer Detection and Diagnosis Research	000	3	9/3/2021	NON-COMPETING CONTINUATION	$592,644
2021	2021	UNIVERSITY OF MIAMI	1600 NW 10 AVE	MIAMI	FL	33136	MIAMI-DADE	USA	Cancer Detection and Diagnosis Research	001	3	9/22/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $592,644

Issue Date FY: 2020 ( Subtotal = $604,709 )
2020	2020	UNIVERSITY OF MIAMI	1600 NW 10 AVE	MIAMI	FL	33136	MIAMI-DADE	USA	Cancer Detection and Diagnosis Research	001	2	8/28/2020	NON-COMPETING CONTINUATION	$604,709
2020	2019	UNIVERSITY OF MIAMI	1600 NW 10 AVE	MIAMI	FL	33136	MIAMI-DADE	USA	Cancer Detection and Diagnosis Research	000	1	11/6/2019	NEW	$0
														Subtotal = $604,709

Issue Date FY: 2019 ( Subtotal = $629,523 )
2019	2019	UNIVERSITY OF MIAMI	1600 NW 10 AVE	MIAMI	FL	33136	MIAMI-DADE	USA	Cancer Detection and Diagnosis Research	000	1	9/16/2019	NEW	$629,523
														Subtotal = $629,523

Grand Total All Awards = $2,900,940

Top

All Categories

About

Search

Reports

Data Submission

Award Information

MRI Imaging and Biomarkers for Early Detection of Aggressive Prostate Cancer

Award Number: U01CA239141

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/16/2019

PERIOD OF PERFORMANCE END DATE: 08/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer